Hydroxamate Compounds for Metabolic Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PPARγ agonists, such as thiazolidinediones, effectively treat metabolic disorders but trigger side effects like sodium reabsorption and weight gain due to high PPARγ activity, while compounds with reduced PPARγ activity struggle to stimulate brown adipose tissue differentiation and UCP1 protein increase.
Innovation Solution
Development of hydroxamate compounds with reduced PPARγ binding and activation, specifically formulated to stimulate brown adipose tissue differentiation and increase UCP1 protein levels without augmenting sodium reabsorption, for treating metabolic disorders like diabetes, obesity, and dyslipidemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional thiazolidinediones are used as PPARγ agonists, then metabolic disorders are effectively treated, but side effects like sodium reabsorption and weight gain occur
Solution Approach 1:
The patent extracts and isolates the beneficial metabolic effects from the harmful PPARγ-mediated side effects by developing compounds that act through alternative pathways. The hydroxamate compounds stimulate brown adipose tissue thermogenesis and improve insulin sensitivity without activating PPARγ, thereby separating the therapeutic benefits from the adverse effects of sodium reabsorption and weight gain.
Solution Approach 2:
The invention introduces brown adipose tissue activation and UCP1-mediated thermogenesis as an intermediary mechanism to achieve metabolic benefits. Instead of directly activating PPARγ, the compounds use brown fat thermogenesis as a mediator to improve glucose metabolism and insulin sensitivity, thereby achieving therapeutic effects through an alternative pathway that avoids PPARγ-related side effects.
2Object-generated harmful factors
If compounds with reduced PPARγ activity are used, then side effects are reduced, but brown adipose tissue differentiation and UCP1 protein increase are not stimulated
Solution Approach 1:
The patent segments the functional requirements into two distinct pathways: one for stimulating brown adipose tissue differentiation and UCP1 expression, and another for avoiding PPARγ activation. The hydroxamate compounds are designed to specifically target the brown fat pathway while leaving PPARγ unactivated, thereby achieving both reduced side effects and maintained therapeutic efficacy.
Solution Approach 2:
The invention changes the molecular parameters of the compounds by using hydroxamate functionality instead of traditional PPARγ-active moieties. This parameter change allows the compounds to bind to and activate brown adipose tissue-specific receptors and pathways, enabling BAT differentiation and UCP1 induction without triggering PPARγ-mediated sodium reabsorption and weight gain.
3Reliability
If PPARγ activation is increased to enhance metabolic benefits, then therapeutic efficacy improves, but sodium reabsorption and weight gain side effects worsen
Solution Approach 1:
Instead of activating PPARγ to achieve metabolic benefits, the patent inverts the approach by using PPARγ-independent mechanisms. The hydroxamate compounds stimulate brown adipose tissue thermogenesis and improve metabolism through alternative pathways, effectively achieving the same therapeutic goals by going the opposite route of traditional PPARγ agonism.
Data Source
AI summary
The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neurodegenerative disorder (e.g., Alzheimer's disease, Parkinson's disease, or Huntington's disease), or any combination thereof. Moreover, the present invention also provides methods of treatment for these diseases or disorders.